CPhI report predicts growth in outsourcing for sterile injectables

In the latest installment of CPhI annual reports, Vivek Sharma, CEO of Piramal Pharma Solutions, predicts that there will be a 10% annual growth in the outsourcing of sterile injectables over the next 5 years and that U.S. producers will continue to be favored for that work, followed by CMOs in Western Europe. Among the factors driving that growth, he predicts, will be a preference to outsource high-potency products, demand from companies looking for a backup supplier for a product, growth in emerging markets for generics, and the need for specialized technology from contractors. He pointed specifically to the need for drug delivery systems such as liposomes, PEGlyation, and depot injections as targeted drugs become more a part of the healthcare picture. Release

Suggested Articles

Lonza CEO Marc Funk is leaving for "personal reasons" after less than a year in the top job. 

Drugmakers have voluntarily recalled their generic Zantac from the U.S. market after the FDA raised concerns, but it has not been without a cost.

Just weeks after selling the sterile manufacturing assets of its Kyowa operation in Japan, it has unloaded the rest of its Kyowa drugmaking operation.